Athanasios Zouzos

Abstract In PREDIX LumB patients with estrogen receptor positive and human epidermal growth factor receptor negative (ER + /HER2-) breast cancer > 20 mm and/or with lymph node metastasis were randomized 1:1 to receive either paclitaxel weekly for 12 weeks followed by palbociclib and endocrine therapy for 12 weeks (arm A), or the reverse sequence (arm B).

Submitted: 30 October 2025 You are already at the latest version Background The diagnostic process of probable benign breast lesions involves a 1–40% upgrade rate to malignancy comparing biopsy (cytology and/or histology) to surgery. Within a previous performed clinical randomized trial, we aimed to examine the diagnostic discrepancies between prior biopsy results and subsequent vacuum-assisted excision (VAE).

Papillary thyroid cancer is associated with lymph node metastasis and tumor recurrence that need repeated surgery, entailing surgical challenges with a high risk of complications such as nerve damage and bleeding. Magseed is a metal coil used to detect non-palpable lesions and is an established modality in breast cancer surgery. In this case series, we explore the feasibility of Magseed in metastasis surgery of papillary thyroid cancer.